Roundview Capital LLC Purchases 25,607 Shares of SPDR S&P Biotech ETF $XBI

Roundview Capital LLC lifted its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 571.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 30,087 shares of the exchange traded fund’s stock after acquiring an additional 25,607 shares during the quarter. Roundview Capital LLC’s holdings in SPDR S&P Biotech ETF were worth $3,669,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in SPDR S&P Biotech ETF by 27.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock worth $1,356,582,000 after purchasing an additional 2,900,633 shares in the last quarter. Bessemer Group Inc. lifted its holdings in SPDR S&P Biotech ETF by 13.5% during the 4th quarter. Bessemer Group Inc. now owns 1,853,232 shares of the exchange traded fund’s stock worth $225,965,000 after purchasing an additional 220,244 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in SPDR S&P Biotech ETF by 40.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,226,147 shares of the exchange traded fund’s stock worth $122,906,000 after purchasing an additional 353,351 shares in the last quarter. Greenhouse Funds LLLP lifted its holdings in SPDR S&P Biotech ETF by 16.6% during the 3rd quarter. Greenhouse Funds LLLP now owns 675,975 shares of the exchange traded fund’s stock worth $67,733,000 after purchasing an additional 96,308 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in SPDR S&P Biotech ETF by 1,042,265.6% during the 4th quarter. Assetmark Inc. now owns 635,843 shares of the exchange traded fund’s stock worth $77,528,000 after purchasing an additional 635,782 shares in the last quarter.

SPDR S&P Biotech ETF Stock Performance

Shares of XBI opened at $133.35 on Wednesday. The stock’s 50-day simple moving average is $130.23 and its 200 day simple moving average is $125.49. The stock has a market capitalization of $8.51 billion, a price-to-earnings ratio of 11.47 and a beta of 0.85. SPDR S&P Biotech ETF has a 52-week low of $78.06 and a 52-week high of $139.19.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.